Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

CONCLUSIONS: These results suggest that caplacizumab was efficacious and well tolerated in patients with aTTP who experienced a disease exacerbation during double-blind treatment in HERCULES.
PMID: 31691462 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - November 4, 2019 Category: Hematology Authors: Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F Tags: J Thromb Haemost Source Type: research